Top

Published in:

01-12-2009 | Letter to the Editor

The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features

Authors: E. Barroso, G. Pita, J. I. Arias, P. Menendez, P. Zamora, M. Blanco, J. Benitez, G. Ribas

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

Fanconi anemia (FA) family of proteins participates in the DNA repair pathway by homologous recombination, and it is currently formed by 13 genes. Some of these proteins also confer susceptibility to hereditary breast and ovarian cancer (HBOC), since FANCD1 is the BRCA2 breast cancer susceptibility gene, and FANCN/PALB2 and FANCJ/BRIP1 explain 2% of non-BRCA1/2 HBOC families. Thus, there is an important connection between FA and BRCA pathways. In a previous case–control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35). In order to know whether variants in other FA genes could also be involved in this association, we have extended our study with the rest of FA genes and some others implicated in the BRCA pathway. We have also analyzed the correlation with survival, nodal metastasis and hormonal receptors (ER− and PR−). A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR− status.

Available only for authorised users

Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71CrossRefPubMed

Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792CrossRefPubMed

Stewart G, Elledge SJ (2002) The two faces of BRCA2, a FANCtastic discovery. Mol Cell 10:2–4CrossRefPubMed

Thorstenson YR, Roxas A, Kroiss R et al (2003) Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63:3325–3333PubMed

Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241CrossRefPubMed

Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167CrossRefPubMed

Liang F, Han M, Romanienko PJ, Jasin M (1998) Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci USA 95:5172–5177CrossRefPubMed

Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) Brca1 controls homology-directed DNA repair. Mol Cell 4:511–518CrossRefPubMed

Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263–272CrossRefPubMed

10.

Wang X, D’Andrea AD (2004) The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair (Amst) 3:1063–1069CrossRef

11.

Thompson E, Dragovic RL, Stephenson SA et al (2005) A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer. BMC Cancer 5:43CrossRefPubMed

12.

Fei P, Yin J, Wang W (2005) New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein. Cell Cycle 4(8):80–86PubMed

13.

Kitao H, Yamamoto K, Matsushita N et al (2006) Functional interplay between BRCA2/FancD1 and FancC in DNA repair. J Biol Chem 281:21312–21320CrossRefPubMed

14.

Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609CrossRefPubMed

15.

Hussain S, Wilson JB, Medhurst AL et al (2004) Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 13:1241–1248CrossRefPubMed

16.

Gordon SM, Alon N, Buchwald M (2005) FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway. J Biol Chem 280:36118–36125CrossRefPubMed

17.

Wang Z, Li M, Lu S, Zhang Y, Wang H (2006) Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 5:256–260PubMedCrossRef

18.

Hussain S, Witt E, Huber PA et al (2003) Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 12:2503–2510CrossRefPubMed

19.

Sims AE, Spiteri E, Sims RJ et al (2007) FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 14:564–567CrossRefPubMed

20.

Litman R, Peng M, Jin Z et al (2005) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265CrossRefPubMed

21.

Meetei AR, Yan Z, Wang W (2004) FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 3:179–181PubMed

22.

Meetei AR, Medhurst AL, Ling C et al (2005) A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 37:958–963CrossRefPubMed

23.

Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788–6793CrossRefPubMed

24.

Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8:735–748CrossRefPubMed

25.

Garcia MJ, Benitez J (2008) The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. Clin Transl Oncol 10:78–84CrossRefPubMed

26.

Jacquemont C, Taniguchi T (2007) The Fanconi anemia pathway and ubiquitin. BMC Biochem 8(Suppl 1):S10CrossRefPubMed

27.

Gatei M, Zhou BB, Hobson K et al (2001) Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 276:17276–17280CrossRefPubMed

28.

Yu YM, Pace SM, Allen SR, Deng CX, Hsu LC (2008) A PP1-binding motif present in BRCA1 plays a role in its DNA repair function. Int J Biol Sci 4:352–361PubMed

29.

Lyakhovich A, Surralles J (2007) New roads to FA/BRCA pathway: H2AX. Cell Cycle 6:1019–1023PubMed

30.

Nijman SM, Huang TT, Dirac AM et al (2005) The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 17:331–339CrossRefPubMed

31.

Barroso E, Milne RL, Fernandez LP et al (2006) FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 27:1930–1937CrossRefPubMed

32.

Freedman ML, Penney KL, Stram DO et al (2004) Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort. Hum Mol Genet 13:2431–2441CrossRefPubMed

33.

Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA, Benitez J (2008) The molecular pathology of hereditary breast cancer. Pathobiology 75:85–94CrossRefPubMed

34.

Baynes C, Healey CS, Pooley KA et al (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27CrossRefPubMed

35.

Narayan G, Arias-Pulido H, Nandula SV et al (2004) Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994–2997CrossRefPubMed

36.

van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585–2588PubMed

37.

Berwick M, Satagopan JM, Ben-Porat L et al (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 67:9591–9596CrossRefPubMed

38.

Tischkowitz M, Easton DF, Ball J, Hodgson SV, Mathew CG (2008) Cancer incidence in relatives of British Fanconi Anaemia patients. BMC Cancer 8:257CrossRefPubMed

39.

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423CrossRefPubMed

40.

Garcia-Closas M, Hall P, Nevanlinna H et al (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4:e1000054CrossRefPubMed

41.

Mavaddat N, Dunning AM, Ponder BA, Easton DF, Pharoah PD (2009) Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers Prev 18:255–259CrossRefPubMed

Title: The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features
Authors: E. Barroso
G. Pita
J. I. Arias
P. Menendez
P. Zamora
M. Blanco
J. Benitez
G. Ribas
Publication date: 01-12-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0439-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling

Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk

Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study

Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer